A Phase I Clinical Trial of UX-GIP001 in the Treatment of Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
24. juli 2026 oppdatert av: Shanghai UniXell Biotechnology Co., Ltd
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of UX-GIP001 (Human GABAergic Interneuron Progenitor Cells Injection) in the Treatment of Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
This is a phase I study (Protocol: UX-GIP001-102) investigating UX-GIP001 Injection, a novel cell therapy product consisting of human GABAergic interneuron progenitor cells (GIP), for treating adult patients with drug-resistant unilateral medial temporal lobe epilepsy (MTLE).
The primary objective is to assess the safety, tolerability, and preliminary efficacy of UX-GIP001.
This is an open-label, single-arm study.
All enrolled participants will receive the active investigational cell therapy.
Seizure frequency and safety parameters will be evaluated by comparing post-transplant outcomes to pre-transplant baselines.
Studieoversikt
Detaljert beskrivelse
Participants will receive UX-GIP001 via stereotactic neurosurgery, preceded by and followed with immunosuppressive therapy.
The study includes a baseline period for eligibility confirmation and a 24-month follow-up phase involving regular safety assessments, neuroimaging , seizure diary logging, and evaluations of quality of life, cognition, and mood.
This pioneering regenerative approach seeks to provide a new treatment strategy for drug-resistant MTLE by addressing the underlying pathophysiology.
Studietype
Intervensjonell
Registrering (Antatt)
12
Fase
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Xianwei Zhi
- Telefonnummer: +86-21-60197620
- E-post: xianweizhi@unixell.com
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100070
- Beijing Tiantan Hospital, Capital Medical University
-
Ta kontakt med:
- Xiaoqiu Shao
-
-
Henan
-
Zhengzhou, Henan, Kina, 450000
- The First Affiliated Hospital of Zhengzhou University
-
Ta kontakt med:
- Qun Wang
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- West China School of Medicine and West China Hospital, Sichuan University
-
Ta kontakt med:
- Dong Zhou, Doctor
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Age 18-75 years (inclusive), male or female;
- Diagnosis of focal epilepsy according to the International League Against Epilepsy (ILAE) 2025 epilepsy classification, with disease duration ≥2 years;
- Clinical presentation consistent with unilateral mesial temporal lobe epilepsy (MTLE);
- Meeting the diagnostic criteria for drug-resistant epilepsy;
- Average focal seizure frequency ≥4 per 28 days within the 3 months prior to screening;
- On a stable dose of anti-seizure medications for ≥1 month prior to enrollment;
- Patient has adequate organ function as follows: absolute neutrophil count ≥2.0×10⁹/L; white blood cell count ≥4.0×10⁹/L; platelet count ≥100×10⁹/L; AST and ALT ≤2.5× upper limit of normal (ULN); total bilirubin ≤1.5× ULN; serum creatinine ≤1.5× ULN; estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m² (calculated using the CKD-EPI formula);
- Women of childbearing potential must have a negative serum pregnancy test during the screening period. All participants and their partners agree to have no plans for pregnancy, sperm donation, or egg donation from the time of signing the informed consent form until 2 years after cell transplantation treatment, and voluntarily adopt contraceptive measures deemed effective by the investigator;
- Patient has good compliance, with a patient diary completion rate ≥80% prior to enrollment.
Exclusion Criteria:
- Epilepsy caused by other/or progressive neurological diseases , or patients - experiencing only focal aware seizures without observable manifestations.
- History of epilepsy surgery.
- History of status epilepticus within 12 months prior to screening.
- Presence of long-term implants in the skull or intracranial space.
- Severe systemic disease or dysfunction.
- Primary or secondary immunodeficiency.
- History of clear suicidal intent, plan, or behavior within one year prior to screening.
- Severe psychiatric disorders.
- History of malignancy within the past 5 years, except for cervical carcinoma in situ, basal cell or squamous cell skin cancer cured for >5 years.
- Pregnant or breastfeeding women.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: UX-GIP001
To dosenivåer vil bli planlagt.
Hver pasient mottar kun én tilsvarende dose av UX-GIP001.
|
Allogeneic human GABAergic interneuron precursors (UX-GIP001) are delivered into the temporal lobe region of the brain.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Incidence and severity of Adverse Events (AEs)/Serious Adverse Events (SAEs)
Tidsramme: From baseline to 6 Months post-treatment
|
From baseline to 6 Months post-treatment
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change from baseline in total and subtype seizure frequency
Tidsramme: From baseline to 2 years post-treatment
|
From baseline to 2 years post-treatment
|
|
Responder rates (≥50% and ≥75% reduction) in total and subtype seizure frequency
Tidsramme: From baseline to 2 years post-treatment
|
From baseline to 2 years post-treatment
|
|
Seizure free rate
Tidsramme: From baseline to 2 years post-treatment
|
From baseline to 2 years post-treatment
|
|
Incidence and severity of AEs/SAEs related to surgery, transplanted cells, and/or immunosuppressive therapy
Tidsramme: From baseline to 2 years post-treatment
|
From baseline to 2 years post-treatment
|
|
Incidence and severity of all AEs/SAEs
Tidsramme: From baseline to 2 years post-treatment
|
From baseline to 2 years post-treatment
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Dong Zhou, Doctor, West China Hospital
- Hovedetterforsker: Xiaoqiu Shao, Doctor, Beijing Tiantan Hospital
- Hovedetterforsker: Qun Wang, Doctor, The First Affiliated Hospital of Zhengzhou University
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
20. august 2026
Primær fullføring (Antatt)
1. juli 2029
Studiet fullført (Antatt)
1. juli 2029
Datoer for studieregistrering
Først innsendt
17. april 2026
Først innsendt som oppfylte QC-kriteriene
30. april 2026
Først lagt ut (Faktiske)
7. mai 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
27. juli 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
24. juli 2026
Sist bekreftet
1. april 2026
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- UX-GIP001-102
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .